Adamas Pharmaceuticals
Market Cap
US$127.2m
Last Updated
2021/01/16 23:24 UTC
Data Sources
Company Financials +
Executive Summary
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Slightly overvalued with concerning outlook.
Share Price & News
How has Adamas Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ADMS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ADMS's weekly volatility (9%) has been stable over the past year.
Market Performance
7 Day Return
-4.3%
ADMS
3.5%
US Biotechs
-1.0%
US Market
1 Year Return
-24.2%
ADMS
36.8%
US Biotechs
19.6%
US Market
Return vs Industry: ADMS underperformed the US Biotechs industry which returned 36.8% over the past year.
Return vs Market: ADMS underperformed the US Market which returned 19.6% over the past year.
Shareholder returns
| ADMS | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.3% | 3.5% | -1.0% |
| 30 Day | -12.7% | 4.5% | 2.2% |
| 90 Day | 0.4% | 19.2% | 11.5% |
| 1 Year | -24.2%-24.2% | 39.0%36.8% | 22.3%19.6% |
| 3 Year | -88.3%-88.3% | 30.5%23.6% | 45.3%35.7% |
| 5 Year | -79.9%-79.9% | 43.9%33.0% | 124.8%99.8% |
Long-Term Price Volatility Vs. Market
How volatile is Adamas Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS): Is Breakeven Near?2 months ago | Simply Wall St
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Just Released Its Third-Quarter Earnings: Here's What Analysts Think3 months ago | Simply Wall St
What Kind Of Shareholders Own Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)?Valuation
Is Adamas Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ADMS ($4.46) is trading below our estimate of fair value ($28.07)
Significantly Below Fair Value: ADMS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ADMS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ADMS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ADMS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ADMS has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.
Next Steps
Future Growth
How is Adamas Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
53.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ADMS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ADMS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ADMS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ADMS's revenue (15.9% per year) is forecast to grow faster than the US market (10.2% per year).
High Growth Revenue: ADMS's revenue (15.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ADMS's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Adamas Pharmaceuticals performed over the past 5 years?
-14.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ADMS is currently unprofitable.
Growing Profit Margin: ADMS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ADMS is unprofitable, and losses have increased over the past 5 years at a rate of 14.6% per year.
Accelerating Growth: Unable to compare ADMS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ADMS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: ADMS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Next Steps
Financial Health
How is Adamas Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: ADMS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ADMS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ADMS has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ADMS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ADMS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ADMS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Adamas Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ADMS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ADMS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ADMS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ADMS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ADMS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.2yrs
Average management tenure
CEO
Neil McFarlane (47 yo)
1.33yrs
Tenure
US$2,523,429
Compensation
Mr. Neil F. Mcfarlane serves as Chief Executive Officer and Director of Adamas Pharmaceuticals, Inc. since September 16, 2019. Mr. Mcfarlane served as Chief Operating Officer of Retrophin, Inc. since Augus...
CEO Compensation Analysis
Compensation vs Market: Neil's total compensation ($USD2.52M) is above average for companies of similar size in the US market ($USD533.86K).
Compensation vs Earnings: Insufficient data to compare Neil's compensation with company performance.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.33yrs | US$2.52m | no data | |
| Chief Financial Officer | 1.17yrs | US$1.09m | 0.091% $ 116.3k | |
| Chief Commercial Officer | 1.67yrs | US$1.40m | 0.0088% $ 11.2k | |
| Head of Corporate Communications | 1.92yrs | no data | no data | |
| Senior Vice President of Sales | no data | no data | no data | |
| Head of Corporate Development | 0.42yr | no data | no data | |
| Head of Human Resources | 1.17yrs | no data | no data | |
| Senior Vice President of Commercial Operations & Market Access | no data | no data | no data | |
| Chief Medical Officer | 0.33yr | no data | no data |
1.2yrs
Average Tenure
47yo
Average Age
Experienced Management: ADMS's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.33yrs | US$2.52m | no data | |
| Independent Director | 16yrs | US$84.71k | 0% $ 0 | |
| Independent Director | 6.83yrs | US$94.71k | 0.046% $ 58.0k | |
| Chairman & Lead Independent Director | 1.33yrs | US$264.88k | 0.21% $ 266.6k | |
| Scientific & Clinical Advisor | no data | no data | no data | |
| Member of Influenza Advisory Board | no data | no data | no data | |
| Scientific & Clinical Advisor | no data | no data | no data | |
| Member of Influenza Advisory Board | no data | no data | no data | |
| Scientific & Clinical Advisor | no data | no data | no data | |
| Member of CNS Advisory Board | no data | no data | no data | |
| Member of Influenza Advisory Board | no data | no data | no data | |
| Member of Influenza Advisory Board | no data | no data | no data |
4.1yrs
Average Tenure
66.5yo
Average Age
Experienced Board: ADMS's board of directors are considered experienced (4.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ADMS insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.
Top Shareholders
Company Information
Adamas Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Adamas Pharmaceuticals, Inc.
- Ticker: ADMS
- Exchange: NasdaqGM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$127.202m
- Shares outstanding: 28.52m
- Website: https://www.adamaspharma.com
Number of Employees
Location
- Adamas Pharmaceuticals, Inc.
- 1900 Powell Street
- Suite 1000
- EmeryVille
- California
- 94608
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ADMS | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Apr 2014 |
| 136 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Apr 2014 |
Biography
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCO...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/16 23:24 |
| End of Day Share Price | 2021/01/15 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.